YTHDF2 is an RNA binding protein that acts as a reader of N6-methyladenosine (m6A) modifications on RNA molecules. The protein has been implicated in various cellular processes, including RNA metabolism, and it has been linked to the progression of several types of cancer. Research has shown that YTHDF2 can promote cancer progression by increasing its binding affinity with m6A-modified mRNAs, leading to mRNA degradation. It has also been reported that YTHDF2 can be post-translationally modified, such as through SUMOylation, which can enhance its function and contribute to tumor growth. Furthermore, YTHDF2 has been identified as a potential therapeutic target in cancer treatment. Its expression or functional abnormalities are associated with the occurrence and metastasis of various tumors, suggesting its role as a potential oncogene and a therapeutic target. In addition to its role in cancer, YTHDF2 has been shown to modulate the role of M2 macrophages in the origin of metastatic tumors and to control antitumor immunity through CD8+ T cells.